High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$894K
$894,493
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
NTLA
S
Intellia Therapeutics, Inc.
BASTA JAMES
• Officer • EVP, General Counsel
Sell to Cover
2026-03-02
$16,688
|
||||||
| NTLA |
Intellia Therapeutics, Inc.
|
Officer • EVP, General Counsel
Sell to Cover
|
2026-03-02 | $16,688 | S | Form 4 |
|
NTLA
S
Intellia Therapeutics, Inc.
Clark Eliana
• Officer • EVP, Chief Technical Officer
Sell to Cover
2026-03-02
$8,364
|
||||||
| NTLA |
Intellia Therapeutics, Inc.
|
Officer • EVP, Chief Technical Officer
Sell to Cover
|
2026-03-02 | $8,364 | S | Form 4 |
| NTLA |
Intellia Therapeutics, Inc.
|
CEO
Equity Compensation
|
2025-12-12 | $58,444x2 | M | Form 4 |
| NTLA |
Intellia Therapeutics, Inc.
|
CEO
Equity Compensation
|
2025-12-11 | $341,220x2 | M | Form 4 |
| NTLA |
Intellia Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-12-11 | $836,384x3 | S | Form 4 |
|
NTLA
S
Intellia Therapeutics, Inc.
Dube Michael P
• Officer • VP, Chief Accounting Officer
Sell to Cover
2025-10-01
$32,518
|
||||||
| NTLA |
Intellia Therapeutics, Inc.
|
Officer • VP, Chief Accounting Officer
Sell to Cover
|
2025-10-01 | $32,518 | S | Form 4 |
|
NTLA
S
Intellia Therapeutics, Inc.
Schultes Birgit C
• Officer • EVP, Chief Scientific Officer
Sell to Cover
2025-10-01
$539
|
||||||
| NTLA |
Intellia Therapeutics, Inc.
|
Officer • EVP, Chief Scientific Officer
Sell to Cover
|
2025-10-01 | $539 | S | Form 4 |